| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development | 1,394 | 1,675 | 2,137 | |
| General and administrative | 1,528 | 1,168 | 1,456 | |
| Total operating expenses | 2,922 | 2,843 | 3,593 | |
| Loss from operations | -2,922 | -2,843 | -3,593 | |
| Interest expense | 5 | 2 | 6 | |
| Other income, net | 59 | 61 | 112 | |
| Total other income, net | 54 | 59 | 106 | |
| Net loss | -2,868 | -2,784 | -3,487 | |
| Basic net loss per common share | -0.38 | -0.58 | -2.32 | |
| Diluted net loss per common share | -0.38 | -0.58 | -2.32 | |
| Weighted average shares used in calculating basic loss per common share | 7,473,898 | 4,797,196 | 1,500,409 | |
| Weighted average shares used in calculating diluted loss per common share | 7,473,898 | 4,797,196 | 1,500,409 | |
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)